Home Page|About us

The Pediatric Infections Research Center (PIRC) of Shahid Beheshti University, M. C. was established in January 2004. Its located in Mofid Children Hospital in the North of Tehran. This hospital has several pediatric departments with an active emergency ward which provides a great source of referral patients.

Username :   
Password :   


News > Meningococcal Vaccine Now Approved for Use in Infants

  Print        Send to Friend

Meningococcal Vaccine Now Approved for Use in Infants

(FDA) The U.S. Food and Drug Administration today approved the use of Menactra in children as young as nine months for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135. Menactra already is approved for use in people ages 2 through 55 years.


Meningococcal disease is a life-threatening illness caused by bacteria that infect the bloodstream (sepsis) and the lining that surrounds the brain and spinal cord (meningitis). Neisseria meningitidis is a leading cause of meningitis in young children. Even with appropriate antibiotics and intensive care, between 10 percent and 15 percent of people who develop meningococcal disease die from the infection. Another 10 percent to 20 percent suffer complications such as brain damage or loss of limb or hearing.




Although the rates of meningococcal disease are low in the United States, infants and toddlers are more susceptible to getting this serious illness. Meningococcal disease is particularly dangerous because it progresses rapidly and can cause death within hours. Early symptoms are often difficult to distinguish from influenza and other common illnesses.


“The highest rate of meningococcal disease occurs in children under one year of age. With today’s approval, Menactra can now be used in children as young as 9 months of age to help prevent this potentially life-threatening disease,” said Karen Midthun, M.D., director of FDAs Center for Biologics Evaluation and Research.


The safety of Menactra in children as young as 9 months was evaluated in four clinical studies in which over 3,700 participants received the vaccine. The most common adverse events reported in children who received Menactra at 9 months and 12 months of age were injection-site tenderness and irritability. Occurrence of fever was comparable to other vaccines routinely recommended for young children.


Menactra is given as a two-dose series beginning at 9-months, three months apart; and the study results showed the vaccine produces antibodies in the blood that are protective against the disease.


Menactra was originally approved on Jan. 14, 2005, for use in individuals ages 11 years through 55 years and was approved in October 2007 for children as young as 2 years. Menactra is manufactured by Sanofi Pasteur Inc. of Swiftwater, Pennsylvania

11:25 - 26/04/2011    /    Number : 332    /    Show Count : 1076


New Articles
weather.ir is down
Visitors` Statistics
 Visitors of page : 18916
 Visitors of day : 93
 Visitors sum : 152257
 Online visitors : 1
 Page load : 0/0938
Home Page|About us|Contact us|Advanced Search
Copyright © 2010 Pedirc.com  -  All rights reserved.